Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 1/2014

01.02.2014 | short review

Breast cancer surveillance: nothing has changed in the past decades (?)

verfasst von: Zsuzsanna Kahán, MD, DSc

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

In the well-developed countries, breast cancer-related mortality rates show decreasing tendency. Relapse occurs only in about one-fourth of all patients. According to randomized studies, no survival benefit is provided in these cases by practising intensive follow-up including instrumental studies to actively search for distant metastases. The most important role of patient surveillance is to detect early-stage, potentially curable isolated local/regional relapses or second primary breast cancers. More and more attention is given to the early detection and treatment of the side-effects of the therapy on the other hand. Even a “minimalist” follow-up practice maintains the relationship with the patient that is important for getting reassurance for compliance with adjuvant endocrine therapies, assistance in case of symptoms of metastasis, or if medical or social decisions are to be made. Sometimes psychological problems occur, which necesitate special support. In routine practice, regular visits including patient history, physical examination, and breast imaging studies on a 6–12 monthly basis for up to 5 years and yearly thereafter with the maintenance of a supportive relationship with the patient are recommended. Chest, abdominal or bone imaging studies, laboratory or tumor marker tests are justified only in suspicion of relapse.
Literatur
1.
Zurück zum Zitat Khatcheressian JL, Hurley P, Bantug E, et al. American Society of Clinical Oncology. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:961–5.PubMedCrossRef Khatcheressian JL, Hurley P, Bantug E, et al. American Society of Clinical Oncology. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:961–5.PubMedCrossRef
2.
Zurück zum Zitat Aebi S, Davidson T, Gruber G, Cardoso F. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22 (suppl 6):vi12–24.PubMed Aebi S, Davidson T, Gruber G, Cardoso F. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22 (suppl 6):vi12–24.PubMed
4.
Zurück zum Zitat Partridge AH, Winer EP, Burstein HJ. Follow-up care of breast cancer survivors. Semin Oncol. 2003;30:817–25.PubMedCrossRef Partridge AH, Winer EP, Burstein HJ. Follow-up care of breast cancer survivors. Semin Oncol. 2003;30:817–25.PubMedCrossRef
5.
Zurück zum Zitat Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA. 1994;271:1593–7.CrossRef Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA. 1994;271:1593–7.CrossRef
6.
Zurück zum Zitat Palli D, Russo A, Saieva C, et al. Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer Follow-up. JAMA. 1999;281:1586.PubMedCrossRef Palli D, Russo A, Saieva C, et al. Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer Follow-up. JAMA. 1999;281:1586.PubMedCrossRef
7.
Zurück zum Zitat GIVIO. Impact of follow-up testing on survival and health-related quality oflife in breast cancer patients. A multicenter randomized controlled trial. JAMA. 1994;271:1587–92.CrossRef GIVIO. Impact of follow-up testing on survival and health-related quality oflife in breast cancer patients. A multicenter randomized controlled trial. JAMA. 1994;271:1587–92.CrossRef
9.
Zurück zum Zitat Kokko R, Hakama M, Holli K. Follow-up cost of breast cancer patients with localized disease after primary treatment: a randomized trial. Breast Cancer Res Treat. 2005;93:255–60.PubMedCrossRef Kokko R, Hakama M, Holli K. Follow-up cost of breast cancer patients with localized disease after primary treatment: a randomized trial. Breast Cancer Res Treat. 2005;93:255–60.PubMedCrossRef
10.
Zurück zum Zitat Rojas MP, Telaro E, Russo A, Moschetti I, Coe L, Fossati R, et al. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev. 2005:CD001768. Rojas MP, Telaro E, Russo A, Moschetti I, Coe L, Fossati R, et al. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev. 2005:CD001768.
11.
Zurück zum Zitat Winchester DP, Sener SF, Khandekar JD, et al. Symptomatology as an indicator of recurrent or metastatic breast cancer. Cancer. 1979;43:956–60.PubMedCrossRef Winchester DP, Sener SF, Khandekar JD, et al. Symptomatology as an indicator of recurrent or metastatic breast cancer. Cancer. 1979;43:956–60.PubMedCrossRef
12.
Zurück zum Zitat Schapira DV, Urban N. A minimalist policy for breast cancer surveillance. JAMA. 1991;265:380–2.PubMedCrossRef Schapira DV, Urban N. A minimalist policy for breast cancer surveillance. JAMA. 1991;265:380–2.PubMedCrossRef
13.
Zurück zum Zitat Lee JE, Park SS, Han W, et al. The clinical use of staging bone scan in patients with breast carcinoma: reevaluation by the 2003 American Joint Committee on Cancer staging system. Cancer. 2005;104:499–503.PubMedCrossRef Lee JE, Park SS, Han W, et al. The clinical use of staging bone scan in patients with breast carcinoma: reevaluation by the 2003 American Joint Committee on Cancer staging system. Cancer. 2005;104:499–503.PubMedCrossRef
14.
Zurück zum Zitat Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287–312.PubMedCrossRef Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287–312.PubMedCrossRef
15.
Zurück zum Zitat Mille D, Roy T, Carrère MO, et al. Economic impact of harmonizing medical practices: compliance with clinical practice guidelines in the follow-up of breast cancer in a French Comprehensive Cancer Center. J Clin Oncol. 2000;18:1718–24.PubMed Mille D, Roy T, Carrère MO, et al. Economic impact of harmonizing medical practices: compliance with clinical practice guidelines in the follow-up of breast cancer in a French Comprehensive Cancer Center. J Clin Oncol. 2000;18:1718–24.PubMed
16.
Zurück zum Zitat Gulliford T, Opomu M, Wilson E, Hanham I, Epstein R. Popularity of less frequent follow up for breast cancer in randomised study: initial findings from the hotline study. BMJ. 1997;314:174–7.PubMedCentralPubMedCrossRef Gulliford T, Opomu M, Wilson E, Hanham I, Epstein R. Popularity of less frequent follow up for breast cancer in randomised study: initial findings from the hotline study. BMJ. 1997;314:174–7.PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Loprinzi CL, Hayes D, Smith T. Doc, shouldn’t we be getting some tests? J Clin Oncol. 2000;18:2345–8.PubMed Loprinzi CL, Hayes D, Smith T. Doc, shouldn’t we be getting some tests? J Clin Oncol. 2000;18:2345–8.PubMed
18.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707–16.PubMedCrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707–16.PubMedCrossRef
19.
Zurück zum Zitat Kahán Z, Hideghéty K, Varga Z. Breast cancer, a heterogeneous disease entity. The very early stages. Springer, Dordrecht; 2011. Chap. 10, the risks of radiotherapy, and how to avoid them. pp. 241–68. Kahán Z, Hideghéty K, Varga Z. Breast cancer, a heterogeneous disease entity. The very early stages. Springer, Dordrecht; 2011. Chap. 10, the risks of radiotherapy, and how to avoid them. pp. 241–68.
20.
Zurück zum Zitat Liljegren G, Lindgren A, Bergh J, et al. Risk factors for local recurrence after conservative treatment in stage I breast cancer. Definition of a subgroup not requiring radiotherapy. Ann Oncol. 1997;8:235–41.PubMedCrossRef Liljegren G, Lindgren A, Bergh J, et al. Risk factors for local recurrence after conservative treatment in stage I breast cancer. Definition of a subgroup not requiring radiotherapy. Ann Oncol. 1997;8:235–41.PubMedCrossRef
21.
Zurück zum Zitat Holmberg L, Wong YN, Tabár L, et al. Mammography casting-type calcification and risk of local recurrence in DCIS: analyses from a randomised study. Br J Cancer. 2013;108:812–9.PubMedCentralPubMedCrossRef Holmberg L, Wong YN, Tabár L, et al. Mammography casting-type calcification and risk of local recurrence in DCIS: analyses from a randomised study. Br J Cancer. 2013;108:812–9.PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Dorr W, Bertmann S, Herrmann T. Radiation induced lung reactions in breast cancer therapy. Modulating factors and consequential effects. Strahlenther Onkol. 2005;181:567–73.PubMedCrossRef Dorr W, Bertmann S, Herrmann T. Radiation induced lung reactions in breast cancer therapy. Modulating factors and consequential effects. Strahlenther Onkol. 2005;181:567–73.PubMedCrossRef
23.
Zurück zum Zitat Johansen J, Overgaard J, Rose C, et al. Cosmetic outcome and breast morbidity in breast-conserving treatment. Acta Oncol. 2002;41:369–80.PubMedCrossRef Johansen J, Overgaard J, Rose C, et al. Cosmetic outcome and breast morbidity in breast-conserving treatment. Acta Oncol. 2002;41:369–80.PubMedCrossRef
24.
Zurück zum Zitat Darby SC, Cutter DJ, Boerma M, et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys. 2010;76:656–65.PubMedCentralPubMedCrossRef Darby SC, Cutter DJ, Boerma M, et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys. 2010;76:656–65.PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Darby S, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300 000 women in US SEER cancer registries. Lancet Oncol. 2005;6:557–65.PubMedCrossRef Darby S, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300 000 women in US SEER cancer registries. Lancet Oncol. 2005;6:557–65.PubMedCrossRef
26.
Zurück zum Zitat Cuzick J, Stewart H, Rutqvist L, et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol. 1994;12:447–53.PubMed Cuzick J, Stewart H, Rutqvist L, et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol. 1994;12:447–53.PubMed
27.
Zurück zum Zitat Kahán Z. Breast cancer, a heterogeneous disease entity. The very early stages. Springer, Dordrecht; 2011. Chap. 12, systemic therapy: selection of patients. Endocrine therapy. pp. 283–304. Kahán Z. Breast cancer, a heterogeneous disease entity. The very early stages. Springer, Dordrecht; 2011. Chap. 12, systemic therapy: selection of patients. Endocrine therapy. pp. 283–304.
28.
Zurück zum Zitat Pagani O, Partridge A, Korde L, et al. Breast International Group; North American Breast Cancer Group Endocrine Working Group. Pregnancy after breast cancer: if you wish, ma’am. Breast Cancer Res Treat. 2011;129:309–17.PubMedCrossRef Pagani O, Partridge A, Korde L, et al. Breast International Group; North American Breast Cancer Group Endocrine Working Group. Pregnancy after breast cancer: if you wish, ma’am. Breast Cancer Res Treat. 2011;129:309–17.PubMedCrossRef
29.
Zurück zum Zitat Balmaña J, Díez O, Rubio IT, Cardoso F, ESMO Guidelines Working Group. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22 (Suppl 6):vi31–4. doi:10.1093/annonc/mdr373. Balmaña J, Díez O, Rubio IT, Cardoso F, ESMO Guidelines Working Group. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22 (Suppl 6):vi31–4. doi:10.1093/annonc/mdr373.
30.
Zurück zum Zitat Kwast AB, Drossaert CH, Siesling S; follow-up working group. Breast cancer follow-up: from the perspective of health professionals and patients. Eur J Cancer Care (Engl). 2013;22:754–64.CrossRef Kwast AB, Drossaert CH, Siesling S; follow-up working group. Breast cancer follow-up: from the perspective of health professionals and patients. Eur J Cancer Care (Engl). 2013;22:754–64.CrossRef
Metadaten
Titel
Breast cancer surveillance: nothing has changed in the past decades (?)
verfasst von
Zsuzsanna Kahán, MD, DSc
Publikationsdatum
01.02.2014
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0136-x

Weitere Artikel der Ausgabe 1/2014

memo - Magazine of European Medical Oncology 1/2014 Zur Ausgabe